Annual Total Expenses
$33.68 M
-$3.54 M-9.52%
31 December 2023
Summary:
Lineage Cell Therapeutics annual total expenses is currently $33.68 million, with the most recent change of -$3.54 million (-9.52%) on 31 December 2023. During the last 3 years, it has risen by +$6.46 million (+23.73%). LCTX annual total expenses is now -50.72% below its all-time high of $68.34 million, reached on 31 December 2015.LCTX Total Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Total Expenses
$7.62 M
+$344.00 K+4.73%
30 September 2024
Summary:
Lineage Cell Therapeutics quarterly total expenses is currently $7.62 million, with the most recent change of +$344.00 thousand (+4.73%) on 30 September 2024. Over the past year, it has dropped by -$332.00 thousand (-4.18%). LCTX quarterly total expenses is now -73.91% below its all-time high of $29.20 million, reached on 31 December 2021.LCTX Quarterly Total Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
LCTX Total Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -9.5% | -4.2% |
| 3 y3 years | +23.7% | -15.8% |
| 5 y5 years | -20.6% | -11.8% |
LCTX Total Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -36.6% | +23.7% | -73.9% | +4.7% |
| 5 y | 5 years | -36.6% | +23.7% | -73.9% | +26.0% |
| alltime | all time | -50.7% | +4109.8% | -73.9% | +873.9% |
Lineage Cell Therapeutics Total Expenses History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $7.62 M(+4.7%) |
| June 2024 | - | $7.28 M(-10.2%) |
| Mar 2024 | - | $8.11 M(-4.1%) |
| Dec 2023 | $33.68 M(-9.5%) | $8.45 M(+6.3%) |
| Sept 2023 | - | $7.95 M(-3.6%) |
| June 2023 | - | $8.25 M(-8.6%) |
| Mar 2023 | - | $9.03 M(+5.5%) |
| Dec 2022 | $37.22 M(-29.9%) | $8.55 M(+3.7%) |
| Sept 2022 | - | $8.25 M(-6.1%) |
| June 2022 | - | $8.79 M(-24.5%) |
| Mar 2022 | - | $11.63 M(-60.2%) |
| Dec 2021 | $53.11 M(+95.1%) | $29.20 M(+222.8%) |
| Sept 2021 | - | $9.04 M(+20.3%) |
| June 2021 | - | $7.52 M(+2.4%) |
| Mar 2021 | - | $7.34 M(+21.4%) |
| Dec 2020 | $27.22 M(-32.5%) | $6.05 M(-14.4%) |
| Sept 2020 | - | $7.07 M(+8.7%) |
| June 2020 | - | $6.50 M(-14.5%) |
| Mar 2020 | - | $7.60 M(-1.3%) |
| Dec 2019 | $40.35 M(-4.9%) | $7.70 M(-10.8%) |
| Sept 2019 | - | $8.64 M(-22.0%) |
| June 2019 | - | $11.07 M(-14.4%) |
| Mar 2019 | - | $12.94 M(+24.6%) |
| Dec 2018 | $42.41 M(-0.1%) | $10.39 M(-2.2%) |
| Sept 2018 | - | $10.62 M(+8.9%) |
| June 2018 | - | $9.75 M(-17.1%) |
| Mar 2018 | - | $11.76 M(+16.1%) |
| Dec 2017 | $42.45 M(-30.7%) | $10.13 M(+1.6%) |
| Sept 2017 | - | $9.98 M(-6.8%) |
| June 2017 | - | $10.70 M(-8.1%) |
| Mar 2017 | - | $11.64 M(-3.1%) |
| Dec 2016 | $61.22 M(-10.4%) | $12.01 M(+20.8%) |
| Sept 2016 | - | $9.95 M(-33.3%) |
| June 2016 | - | $14.91 M(-38.8%) |
| Mar 2016 | - | $24.34 M(+9.4%) |
| Dec 2015 | $68.34 M(+29.9%) | $22.25 M(+24.0%) |
| Sept 2015 | - | $17.94 M(+27.6%) |
| June 2015 | - | $14.07 M(+0.0%) |
| Mar 2015 | - | $14.07 M(-5.2%) |
| Dec 2014 | $52.63 M(+27.2%) | $14.85 M(+17.1%) |
| Sept 2014 | - | $12.68 M(-6.3%) |
| June 2014 | - | $13.53 M(+16.3%) |
| Mar 2014 | - | $11.63 M(-11.2%) |
| Dec 2013 | $41.39 M(+55.0%) | $13.10 M(+21.8%) |
| Sept 2013 | - | $10.76 M(+24.5%) |
| June 2013 | - | $8.64 M(-3.0%) |
| Mar 2013 | - | $8.90 M(+17.5%) |
| Dec 2012 | $26.69 M(+31.2%) | $7.58 M(+16.4%) |
| Sept 2012 | - | $6.51 M(+1.1%) |
| June 2012 | - | $6.44 M(+4.4%) |
| Mar 2012 | - | $6.17 M(+41.9%) |
| Dec 2011 | $20.35 M(+81.3%) | $4.34 M(-19.4%) |
| Sept 2011 | - | $5.39 M(-6.4%) |
| June 2011 | - | $5.76 M(+18.8%) |
| Mar 2011 | - | $4.85 M(+69.3%) |
| Dec 2010 | $11.22 M(+106.1%) | $2.87 M(-12.5%) |
| Sept 2010 | - | $3.27 M(+9.3%) |
| June 2010 | - | $3.00 M(+43.1%) |
| Mar 2010 | - | $2.09 M(-312.6%) |
| Dec 2009 | $5.45 M(+25.9%) | -$984.50 K(-129.1%) |
| Sept 2009 | - | $3.38 M(+119.6%) |
| June 2009 | - | $1.54 M(+27.5%) |
| Mar 2009 | - | $1.21 M(-3.6%) |
| Dec 2008 | $4.33 M | $1.25 M(-6.5%) |
| Sept 2008 | - | $1.34 M(-1.4%) |
| Date | Annual | Quarterly |
|---|---|---|
| June 2008 | - | $1.36 M(+72.6%) |
| Mar 2008 | - | $788.10 K(+28.0%) |
| Dec 2007 | $2.27 M(-22.1%) | $615.90 K(+59.2%) |
| Sept 2007 | - | $386.80 K(-23.3%) |
| June 2007 | - | $504.50 K(-33.7%) |
| Mar 2007 | - | $761.30 K(-7.2%) |
| Dec 2006 | $2.91 M(-0.3%) | $820.20 K(+35.2%) |
| Sept 2006 | - | $606.50 K(-22.7%) |
| June 2006 | - | $784.40 K(+11.6%) |
| Mar 2006 | - | $702.80 K(+2.7%) |
| Dec 2005 | $2.92 M(+10.0%) | $684.40 K(+6.3%) |
| Sept 2005 | - | $644.10 K(-4.8%) |
| June 2005 | - | $676.40 K(-26.2%) |
| Mar 2005 | - | $916.60 K(+15.8%) |
| Dec 2004 | $2.66 M(+18.3%) | $791.30 K(+35.0%) |
| Sept 2004 | - | $586.30 K(-8.9%) |
| June 2004 | - | $643.30 K(+1.1%) |
| Mar 2004 | - | $636.20 K(+1.5%) |
| Dec 2003 | $2.25 M(-7.2%) | $626.60 K(+34.1%) |
| Sept 2003 | - | $467.20 K(-20.8%) |
| June 2003 | - | $590.20 K(+5.0%) |
| Mar 2003 | - | $562.30 K(-29.0%) |
| Dec 2002 | $2.42 M(-33.6%) | $792.10 K(+96.4%) |
| Sept 2002 | - | $403.40 K(-36.4%) |
| June 2002 | - | $634.10 K(+7.1%) |
| Mar 2002 | - | $592.00 K(+21.9%) |
| Dec 2001 | $3.65 M(-29.1%) | $485.80 K(-49.9%) |
| Sept 2001 | - | $970.50 K(-16.0%) |
| June 2001 | - | $1.16 M(+16.6%) |
| Mar 2001 | - | $990.90 K(-9.3%) |
| Dec 2000 | $5.14 M(-24.3%) | $1.09 M(-15.0%) |
| Sept 2000 | - | $1.29 M(-6.8%) |
| June 2000 | - | $1.38 M(-0.5%) |
| Mar 2000 | - | $1.39 M(-7.5%) |
| Dec 1999 | $6.80 M(+183.2%) | $1.50 M(-37.6%) |
| Sept 1999 | - | $2.40 M(+41.2%) |
| June 1999 | - | $1.70 M(+41.7%) |
| Mar 1999 | - | $1.20 M(-7.7%) |
| Dec 1998 | $2.40 M(-50.0%) | - |
| Sept 1998 | - | $1.30 M(+18.2%) |
| June 1998 | - | $1.10 M(-15.4%) |
| June 1998 | $4.80 M(+45.5%) | - |
| Mar 1998 | - | $1.30 M(0.0%) |
| Dec 1997 | - | $1.30 M(+8.3%) |
| Sept 1997 | - | $1.20 M(0.0%) |
| June 1997 | $3.30 M(+57.1%) | $1.20 M(+100.0%) |
| Mar 1997 | - | $600.00 K(-25.0%) |
| Dec 1996 | - | $800.00 K(+14.3%) |
| Sept 1996 | - | $700.00 K(+40.0%) |
| June 1996 | $2.10 M(-19.2%) | - |
| Sept 1995 | - | $500.00 K(-37.5%) |
| June 1995 | $2.60 M(+52.9%) | $800.00 K(+33.3%) |
| Mar 1995 | - | $600.00 K(-14.3%) |
| Dec 1994 | - | $700.00 K(+40.0%) |
| Sept 1994 | - | $500.00 K(-16.7%) |
| June 1994 | $1.70 M(+21.4%) | $600.00 K(+100.0%) |
| Mar 1994 | - | $300.00 K(-25.0%) |
| Dec 1993 | - | $400.00 K(0.0%) |
| Sept 1993 | - | $400.00 K(0.0%) |
| June 1993 | $1.40 M(+75.0%) | $400.00 K(+33.3%) |
| Mar 1993 | - | $300.00 K(-25.0%) |
| Dec 1992 | - | $400.00 K(+33.3%) |
| Sept 1992 | - | $300.00 K(-25.0%) |
| June 1992 | $800.00 K | $400.00 K(+100.0%) |
| Mar 1992 | - | $200.00 K |
FAQ
- What is Lineage Cell Therapeutics annual total expenses?
- What is the all time high annual total expenses for Lineage Cell Therapeutics?
- What is Lineage Cell Therapeutics annual total expenses year-on-year change?
- What is Lineage Cell Therapeutics quarterly total expenses?
- What is the all time high quarterly total expenses for Lineage Cell Therapeutics?
- What is Lineage Cell Therapeutics quarterly total expenses year-on-year change?
What is Lineage Cell Therapeutics annual total expenses?
The current annual total expenses of LCTX is $33.68 M
What is the all time high annual total expenses for Lineage Cell Therapeutics?
Lineage Cell Therapeutics all-time high annual total expenses is $68.34 M
What is Lineage Cell Therapeutics annual total expenses year-on-year change?
Over the past year, LCTX annual total expenses has changed by -$3.54 M (-9.52%)
What is Lineage Cell Therapeutics quarterly total expenses?
The current quarterly total expenses of LCTX is $7.62 M
What is the all time high quarterly total expenses for Lineage Cell Therapeutics?
Lineage Cell Therapeutics all-time high quarterly total expenses is $29.20 M
What is Lineage Cell Therapeutics quarterly total expenses year-on-year change?
Over the past year, LCTX quarterly total expenses has changed by -$332.00 K (-4.18%)